Light-triggerable formulations for the intracellular controlled release of biomolecules.

Abstract:

:New therapies based on the use of biomolecules [e.g., proteins, peptides, and non-coding (nc)RNAs] have emerged during the past few years. Given their instability, adverse effects, and limited ability to cross cell membranes, delivery systems are required to fully reveal their biological potential. Sophisticated nanoformulations responsive to light offer an excellent opportunity for the controlled release of these biomolecules, enabling the control of timing, duration, location, and dosage. In this review, we discuss the design principles for the delivery of biomolecules, in particular proteins and RNA-based therapeutics, by light-triggerable formulations. We further discuss the opportunities offered by these formulations in terms of endosomal escape, as well as their limitations.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Lino MM,Ferreira L

doi

10.1016/j.drudis.2018.01.019

subject

Has Abstract

pub_date

2018-05-01 00:00:00

pages

1062-1070

issue

5

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(17)30225-8

journal_volume

23

pub_type

杂志文章,评审
  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01831-1

    authors: Langston S,Barlocco D

    更新日期:2001-07-01 00:00:00

  • Bioscience industry in metro Atlanta.

    abstract::One of the world's fastest growing cities, Atlanta is the business center of the Southeast U.S. and is rapidly becoming a leader for biotechnology innovation. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/S1359-6446(05)03374-X

    authors: Allen CR

    更新日期:2005-02-15 00:00:00

  • Extending kinome coverage by analysis of kinase inhibitor broad profiling data.

    abstract::The explored kinome was extended with broad profiling using the DiscoveRx and Millipore assay panels. The analysis of the profiling of 3368 selected inhibitors on 456 kinases in the DiscoveRx format delivered several insights. First, the coverage depended on the threshold of the selectivity parameter. Second, the rela...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.01.002

    authors: Jacoby E,Tresadern G,Bembenek S,Wroblowski B,Buyck C,Neefs JM,Rassokhin D,Poncelet A,Hunt J,van Vlijmen H

    更新日期:2015-06-01 00:00:00

  • Mistletoe compound enters clinical trials.

    abstract::A drug has entered clinical trials that contains a recombinant version of the main extract from mistletoe, adn holds promise for cancer patients. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(02)02571-0

    authors: Habeck M

    更新日期:2003-01-15 00:00:00

  • The multiple therapeutic applications of miRNAs for bone regenerative medicine.

    abstract::With the aging of the general population, there is an increasing need for bone defect repair, prompting the development of reliable alternatives to autologous bone grafting, without the usually associated major drawbacks (i.e., limited volume and severe postoperative pain). Given the crucial role that miRNAs appear to...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.007

    authors: Scimeca JC,Verron E

    更新日期:2017-07-01 00:00:00

  • Do enthalpy and entropy distinguish first in class from best in class?

    abstract::A drug molecule should bind to its target with high affinity and selectivity. Because the binding affinity is a combined function of the binding enthalpy and the binding entropy, extremely high affinity requires that both terms contribute favorably to binding. The binding enthalpy, however, is notoriously more difficu...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2008.07.005

    authors: Freire E

    更新日期:2008-10-01 00:00:00

  • Pharmacological treatment of idiopathic pulmonary fibrosis: an update.

    abstract::Idiopathic pulmonary fibrosis (IPF) is a progressive and almost invariably lethal disease that affects primarily older adults. After a decade of negative (or inconsistent) results, two recent clinical trials have demonstrated that slowing disease progression with medication is possible. An improved understanding of di...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.01.001

    authors: Spagnolo P,Wells AU,Collard HR

    更新日期:2015-05-01 00:00:00

  • Modified release drug delivery in veterinary medicine.

    abstract::To successfully research and develop an animal pharmaceutical dosage form, a diverse array of issues covering basic medicine, pharmacology and technology must be addressed. Societal concerns regarding animal and public health, as well as the rapidly changing farming and economic environments, provide additional challe...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02362-0

    authors: Rathbone MJ,Martinez MN

    更新日期:2002-08-01 00:00:00

  • Optimizing the use of open-source software applications in drug discovery.

    abstract::Drug discovery is a time consuming and costly process. Recently, a trend towards the use of in silico computational chemistry and molecular modeling for computer-aided drug design has gained significant momentum. This review investigates the application of free and/or open-source software in the drug discovery process...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03692-5

    authors: Geldenhuys WJ,Gaasch KE,Watson M,Allen DD,Van der Schyf CJ

    更新日期:2006-02-01 00:00:00

  • Accelerated drug discovery by rapid candidate drug identification.

    abstract::The eventual candidate drug (CD) is often already synthesized during early drug discovery but not nominated until much later. To facilitate the rapid identification of a potential CD, a thoroughly worked-out CD target profile (CDTP) with criteria acceptable for the disease target product profile (TPP) is required at t...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2019.03.026

    authors: Bergström F,Lindmark B

    更新日期:2019-06-01 00:00:00

  • The role of the 14-3-3 protein family in health, disease, and drug development.

    abstract::14-3-3 proteins regulate intracellular signaling pathways, such as signal transduction, protein trafficking, cell cycle, and apoptosis. In addition to the ubiquitous roles of 14-3-3 isoforms, unique tissue-specific functions are also described for each isoform. Owing to their role in regulating cell cycle, protein tra...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.09.012

    authors: Aghazadeh Y,Papadopoulos V

    更新日期:2016-02-01 00:00:00

  • Strategies for brain-targeting liposomal delivery of small hydrophobic molecules in the treatment of neurodegenerative diseases.

    abstract::Neurodegenerative diseases (NDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), threaten the health of an ever-growing number of older people worldwide; so far, there are no effective cures. Significant efforts have been devoted to developing new drugs for NDs in recent years, and some small molecul...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.11.001

    authors: Wang ZY,Sreenivasmurthy SG,Song JX,Liu JY,Li M

    更新日期:2019-02-01 00:00:00

  • Analysis of clinical trials of new drugs in China as of 2019.

    abstract::The research and development (R&D) of new drugs indicates scientific progress and economic development. However, little is known regarding ongoing or recent clinical trials in China. We analyzed data from clinical trials published before December 31, 2019, and found that the annual registration numbers are increasing ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2020.09.030

    authors: Lin L,Chen Y,Yan L,Liu Y,Ni J,Yang H,Li H

    更新日期:2020-12-01 00:00:00

  • The role of fragment-based and computational methods in polypharmacology.

    abstract::Polypharmacology-based strategies are gaining increased attention as a novel approach to obtaining potentially innovative medicines for multifactorial diseases. However, some within the pharmaceutical community have resisted these strategies because they can be resource-hungry in the early stages of the drug discovery...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.08.002

    authors: Bottegoni G,Favia AD,Recanatini M,Cavalli A

    更新日期:2012-01-01 00:00:00

  • Improved mouse models and advanced genetic and genomic technologies for the study of neutrophils.

    abstract::Mice have been excellent surrogates for studying neutrophil biology and, furthermore, murine models of human disease have provided fundamental insights into the roles of human neutrophils in innate immunity. The emergence of novel humanized mice and high-diversity mouse populations offers the research community innova...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.03.018

    authors: Hosur V,Skelly DA,Francis C,Low BE,Kohar V,Burzenski LM,Amiji MM,Shultz LD,Wiles MV

    更新日期:2020-06-01 00:00:00

  • Functionalizing bioinks for 3D bioprinting applications.

    abstract::3D bioprinting has emerged as the intersection between chemistry, biology and technology. Through its integration of cells, biocompatible materials and robotic-controlled dispensing systems, the process enables the production of structures that are biomimetic and functional, thus revolutionizing the concept of tissue ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.09.012

    authors: Parak A,Pradeep P,du Toit LC,Kumar P,Choonara YE,Pillay V

    更新日期:2019-01-01 00:00:00

  • Use of Benford's law in drug discovery data.

    abstract::Benford's law states that the distribution of the first digit of many data sets is not uniform. The first digit of any random number will be 1 almost 30% of the time, and larger digits occur as the first digit with lower and lower frequency, to the point where 9 occurs as a first digit only 5% of the time. Here, we de...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2010.03.003

    authors: Orita M,Moritomo A,Niimi T,Ohno K

    更新日期:2010-05-01 00:00:00

  • The TNF superfamily is on the TRAIL to BlyS.

    abstract::Highlights of the 9th (Biennial) International Congress on TNF-Related Cytokines (30 October-2 November 2002; The Manchester Grand Hyatt, San Diego, CA, USA. ...

    journal_title:Drug discovery today

    pub_type:

    doi:10.1016/s1359-6446(02)02592-8

    authors: Steed PM,Hubert RS

    更新日期:2003-02-01 00:00:00

  • Recombinant high-density lipoproteins and their use in cardiovascular diseases.

    abstract::The unique anti-atherosclerosis abilities and other cardioprotective properties make high-density lipoprotein (HDL) a promising solution in treating cardiovascular diseases. A number of studies showed that HDL-based therapy was well tolerated and has great potential in the future. Among all these new agents, the most ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.08.010

    authors: Cao YN,Xu L,Han YC,Wang YN,Liu G,Qi R

    更新日期:2017-01-01 00:00:00

  • New avenues to target Wnt/β-catenin signaling.

    abstract::Wnt/β-catenin signaling is an evolutionarily conserved signaling cascade with imperative roles during development and in adult stem cell maintenance. Hyperactivation of Wnt/β-catenin drives various cancers, whereas hypoactivation underlies bone malformations and neurodegenerative disorders. Although several small mole...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.11.007

    authors: Verkaar F,Zaman GJ

    更新日期:2011-01-01 00:00:00

  • Chemical ligands, genomics and drug discovery.

    abstract::The sequencing of the human genome and numerous pathogen genomes has resulted in an explosion of potential drug targets. These targets represent both an unprecedented opportunity and a technological challenge for the pharmaceutical industry. A new strategy is required to initiate small-molecule drug discovery with set...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01468-9

    authors: Lenz GR,Nash HM,Jindal S

    更新日期:2000-04-01 00:00:00

  • FDA-approved drug labeling for the study of drug-induced liver injury.

    abstract::Drug-induced liver injury (DILI) is a leading cause of drugs failing during clinical trials and being withdrawn from the market. Comparative analysis of drugs based on their DILI potential is an effective approach to discover key DILI mechanisms and risk factors. However, assessing the DILI potential of a drug is a ch...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2011.05.007

    authors: Chen M,Vijay V,Shi Q,Liu Z,Fang H,Tong W

    更新日期:2011-08-01 00:00:00

  • Organometallic compounds in oncology: implications of novel organotins as antitumor agents.

    abstract::Since the introduction of cisplatin in cancer therapy, metal complexes and organometallic compounds have been gaining growing importance in oncology. The impressive clinical effectiveness of cisplatin is limited by significant side effects and the emergence of drug resistance. Thus, novel classic and unconventional Pt...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.02.002

    authors: Alama A,Tasso B,Novelli F,Sparatore F

    更新日期:2009-05-01 00:00:00

  • Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA.

    abstract::Chronic infection with hepatitis B virus (HBV) often leads to the development of liver cancer and cirrhosis, creating immense sociological, clinical and economic burdens worldwide. Although current anti-HBV medications manage to control the disease progression and help restore normal liver functions, they often fail t...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.01.008

    authors: Ahmed M,Wang F,Levin A,Le C,Eltayebi Y,Houghton M,Tyrrell L,Barakat K

    更新日期:2015-05-01 00:00:00

  • Mining the GEMS--a novel platform technology targeting post-transcriptional control mechanisms.

    abstract::The physiological levels of many clinically important proteins are regulated through cellular mechanisms that control the stability and translational efficiency of mRNA. These post-transcriptional processes, which play a critical role in the regulation of gene expression, depend on interactions of specific trans-actin...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.05.009

    authors: Bhattacharyya A,Trotta CR,Peltz SW

    更新日期:2007-07-01 00:00:00

  • New ways to treat bacterial infections.

    abstract::There is an urgent need for fresh approaches to the treatment of bacterial infections because of the changing patterns of infectious disease and the emergence of bacterial strains resistant to current antibiotics. Modification of the cell phenotype to sensitize bacteria to components of the hosts' immune system or to ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02498-4

    authors: Taylor PW,Stapleton PD,Paul Luzio J

    更新日期:2002-11-01 00:00:00

  • Treat the brain and treat the periphery: toward a holistic approach to major depressive disorder.

    abstract::The limited medication for major depressive disorder (MDD) against an ever-rising disease burden presents an urgent need for therapeutic innovations. During recent years, studies looking at the systems regulation of mental health and disease have shown a remarkably powerful control of MDD by systemic signals. Meanwhil...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.03.015

    authors: Zheng X,Zhang X,Wang G,Hao H

    更新日期:2015-05-01 00:00:00

  • Chemical proteomics and its application to drug discovery.

    abstract::The completion of the human genome sequencing project has provided a flood of new information that is likely to change the way scientists approach the study of complex biological systems. A major challenge lies in translating this information into new and better ways to treat human disease. The multidisciplinary scien...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:

    authors: Jeffery DA,Bogyo M

    更新日期:2004-01-15 00:00:00

  • The ELF Honest Data Broker: informatics enabling public-private collaboration in a precompetitive arena.

    abstract::New precompetitive ways of working in the pharmaceutical industry are driving the development of new informatics systems to enable their execution and management. The European Lead Factory (ELF) is a precompetitive, 30-partner collaboration between academic groups, small-medium enterprises and pharmaceutical companies...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2015.11.005

    authors: Paillard G,Cochrane P,Jones PS,van Hoorn WP,Caracoti A,van Vlijmen H,Pannifer AD

    更新日期:2016-01-01 00:00:00

  • Enhancing the potential preclinical and clinical benefits of quercetin through novel drug delivery systems.

    abstract::Quercetin is reported to have numerous pharmacological actions, including antidiabetic, anti-inflammatory and anticancer activities. The main mechanism responsible for its pharmacological activities is its ability to quench reactive oxygen species (ROS) and, hence, decrease the oxidative stress responsible for the dev...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.11.001

    authors: Khursheed R,Singh SK,Wadhwa S,Gulati M,Awasthi A

    更新日期:2020-01-01 00:00:00